At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 45 enrolled
Drug / intervention
Placebo +4 moredrug
Likely dose
PG-760564 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of PG 760564 Administered Twice Daily to Healthy Male and Female Volunteers for 14 Days (27 Doses).
In Brief
A Phase 1 clinical trial evaluating Placebo and PG-760564 for Healthy. Completed, enrolled 45 participants across 1 site.
Detailed Summary
This study is a multiple ascending dose study to Assess the Safety, Tolerability, and Pharmacokinetics of orally dosed PG 760564 Administered Twice Daily to Healthy Male and Female Volunteers for 14 Days (27 Doses).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2005
Primary CompletionJan 2006
First PostedNov 2008
TodayJul 2026
First PostedNov 14, 2008
Enrollment StartAug 1, 2005
Primary CompletionJan 1, 2006
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.6 years ago
Interventions
Placebodrug
oral capsule, 2x/day for 14 days
PG-760564drug
oral capsule, 50 mg, 2x/day for 14 days
PG-760564drug
oral capsule, 100mg, 2x/day for 14 days
PG-760564drug
oral capsule, 200 mg, 2x/day for 14 days
PG-760564drug
oral capsule, 400 mg, 2x/day for 14 days